- For Quality Assurance: the recall highlights the importance of rapid product identification and controlled recall execution.
- For Manufacturing and QC: the case puts particulate control in injectable products under renewed attention.
- For Regulatory Affairs: accurate communication and documentation remain critical while the affected product moves through the recall process.
Baxter Recall Targets Two VIAFLEX Saline Lots Over Particulate Risk
Baxter initiated the voluntary nationwide recall after identifying the potential presence of fiberglass particulate matter in two lots of its 0.9% Sodium Chloride Injection, USP.
The product comes in 500 mL VIAFLEX plastic containers. It provides water and electrolytes and can also serve as a priming solution during hemodialysis procedures. FDA states that the affected product was distributed between July 31 and August 3, 2026, to healthcare providers and distributors in selected U.S. states.
| Product detail | Affected information |
|---|---|
|
Product code |
2B1323Q |
|
Lots |
Y495523 and Y495523A |
|
Expiration |
October 31, 2027 |
|
NDC |
0338-0049-03 |
|
Container |
500 mL VIAFLEX plastic container |
Importantly, the recall concerns the potential presence of fiberglass particles. The published announcement does not establish the underlying manufacturing root cause.
Why Fiberglass Particles in IV Saline Raise Serious Patient-Safety Concerns
Intravenous products enter the bloodstream directly. Therefore, foreign particulate matter can create serious clinical risks.
Baxter stated that fiberglass particles could contribute to blood-vessel blockage and clotting. These effects could reduce blood flow to vital organs or cause pulmonary embolism. The announcement also identifies possible vein irritation, inflammatory reactions, worsening of existing infections and allergic reactions.
However, Baxter had received no reports of adverse events related to the issue as of August 25, 2026.
This distinction matters. The recall represents a potential product-quality and patient-safety risk, but the published information does not report related injuries.
Hospitals and Distributors Told to Stop Using Affected Baxter Saline Lots
Healthcare facilities and distributors should immediately discontinue use of affected units and return them according to their established processes. Baxter is contacting customers with instructions for identifying and returning the products.
For pharmaceutical quality teams, the immediate lesson is equally practical:
- Confirm whether affected lot numbers remain in inventory.
- Segregate affected units according to established recall procedures.
- Maintain traceable records of identification, removal and return.
- Review any complaints or quality events involving the affected lots.
If particulate matter appears in an injectable product, which evidence would your investigation review first: incoming materials and packaging, manufacturing records, or inspection and release data?
The correct investigation path depends on the available evidence. The current recall announcement does not identify the source of the potential fiberglass contamination.
What FDA and Baxter Updates Could Reveal Next About the Saline Recall
Quality teams should watch for further Baxter or FDA updates concerning the recall scope, any newly reported adverse events, and the eventual regulatory status of the recall. Any future information about the source of the particulate issue would also be significant for manufacturing and quality professionals.
How Quality Systems Can Strengthen Recall and Particulate-Risk Response
Zamann Pharma’s Quality Management System service supports activities including deviation and non-conformity management, CAPA, market complaints, batch review and Annex 1-related quality-system work. Teams reviewing how effectively their QMS handles product-quality events can explore this support when additional specialist input is useful.
Source: Ons.Org